NEW YORK – Precision medicine firm Lucence Diagnostics announced on Friday that its laboratory in Singapore has been CLIA certified.
As a result, Lucence can receive patient specimens from the US for testing with its LiquidHallmark liquid biopsy blood test. The test detects cancer-causing gene mutations and viruses present in 14 types of cancers, the company said. According to its website, Lucence's liquid biopsy tests use amplicon-based technology to detect cancer signals in blood "more accurately through amplification."
The laboratory also has College of American Pathologist and ISO 15189 accreditations. Lucence said it is the first regional laboratory in Southeast Asia to demonstrate compliance with US federal regulatory standards.
The Singapore-based firm has a variety of other cancer screening tests, including the LumiRisk, a multi-cancer blood test that detects gene mutations associated with hereditary cancers, and the NPC Gold, a next-generation screening test for early detection of nasopharyngeal cancer